David Brown PhD - Executive Director (Chairman)
David was appointed Chairman of Amura in October 2005. He has over thirty years experience in the pharmaceutical industry both in research and in senior executive roles. He served with four of the top ten Pharma companies: Zeneca, Pfizer, Glaxo, and most recently with F. Hoffman La-Roche as Global Head of Drug Discovery, Roche Pharma. He has extensive experience of pharmaceutical R&D in all phases from early discovery through clinical trials and has experience of leading research in all major disease areas. Whilst at Pfizer he was named co-inventor on the patent for Viagra, and he led the team that developed Viagra through to proof of concept (clinical efficacy) in man. At Roche, David also served on the committee responsible for clinical drug development and he was a core member of the Business Development Committee responsible for in-licensing of products and for technology agreements and acquisitions. David received his PhD in Chemistry from the University of Bristol.

Daniel Roach PhD - General Manager (Executive Director)
Daniel came to Cambridge in 1985 to join PA Consulting Group, becoming Business Development Manager for the Biotechnology Group. In 1993, he joined Advanced Technology Management Limited (ATM), a company established by Alan Goodman which has been involved in forming and seeding nine companies, seven of which subsequently listed on Stock Exchanges - Acambis, Chiroscience, CeNeS, Core, Lidco, Oxford Biomedica and Salix. He was a co-founder of Peptide Therapeutics (now Acambis) in 1993 where he was Commercial Director, CeNeS in 1996 where he was CEO from 1997-2002, Amura in 1997 and Avlar in 1998. He is currently an investment director of Avlar, the ATM group of companies, Medical Device Innovations and Purely Proteins. He has recently been appointed Entrepreneur in Residence at the Centre for Entrepreneurial Learning and to the Greater Cambridge Partnership (GCP) Operating Board. In addition, he has been a board trustee of the Babraham Institute and Chairman of ERBI. He was one of the first students to read biochemistry at the University of Swansea and has a PhD in enzymology from Bath University, funded by Porton Down.

Nick Flinn PhD – Head of Preclinical Development
Nick is a qualified Pharmacist and obtained his Pharmacy degree (1991) and his PhD in Medicinal Chemistry (1996) from The School of Pharmacy, University of London. Nick has extensive knowledge in drug metabolism, pharmacokinetics, formulation and pharmacological assessment of new chemical entities. He has worked for a number of drug discovery companies, including Peptide Therapeutics (now Acambis), Medivir and Incenta. He is Head of Preclinical Development and is responsible for bringing compounds through lead optimisation and early preclinical proof of concept animal models and toxicology studies. Nick holds a formal project management qualification and has great experience in overseeing and managing studies contracted out to external organisations. His role also includes business development, and Nick is responsible for pursuing partnering opportunities and managing the out-licensing of Amura's assets.